14.03.2013 - Finnish Orion Pharma has presented Phase II results suggesting its first-in-class Alzheimer drug ORM-12741 improves memory.
A Phase IIa study on 100 patients with moderate Alzheimer's disease, which dosed the active arm with 60 milligrams or 200 milligrams of ORM-12741 plus standard cholinesterase treatment and memantine, suggested a slight improvement (+4%) in memory tests. In contrast patients receiving placebo twice daily instead of ORM-12741 over three months worsened by 33%.
Orion's candidate drug is the first to target the alpha-2C adrenergic receptor, which is expressed mainly in the CNS (striatum and hippocampus) and has a role as physiological fine tuner of synaptic neurotransmission.
"Currently, there are still only a handful of Alzheimer's drugs on the market and they have only moderate effects on the symptoms of the disease," said study author Dr. Juha Rouru of Orion Pharma. "Anytime you have a drug that targets a new pathway in the brain and shows effectiveness in clinical trials, it is exciting."
Orion has already finished pre-clinical development of another alpha-2c adrenergic receptor in Alzheimer, which was licenced from Polish Selvita, and is in talks with potential partners who want to advance ORM-12741.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.